Tags : Clementia Pharmaceuticals

Ipsen to Acquire Clementia Pharmaceuticals for $1.31B to Expand its

Shots: Ipsen to acquire Clementia Pharmaceuticals in all stock transaction, with its lead candidate palovarotene, for $25/share making the total deal value of $1.04B In H2’19, Ipsen plans to file NDA to the US FDA for Palovarotene if approved, Ipsen will pay regulatory milestone as contingent value right (CVR) at $6/share totaling $263M milestone Palovarotene […]Read More